ACE inhibitors for secondary prevention after myocardial infarction in patients with left ventricular dysfunction

Evidence Summaries

Level of Evidence = A
ACE inhibitors reduce mortality, hospitalisation for congestive heart failure, and recurrent non-fatal myocardial infarction in people with left ventricular dysfunction after myocardial infarction.

A topic in Clinical Evidence 1 summarizes the evidence on ACE inhibitors in patients with myocardial infarction and left ventricular dysfunction. A systematic review of 3 RCTs (5,966 people). ACE inhibitors significantly reduced mortality (OR 0.74, 95% CI 0.66 to 0.83, NNT 17 during 2 years), hospitalisation for congestive heart failure (OR 0.73, 95% CI 0.63 to 0.85, NNT 28) and recurrent non-fatal myocardial infarction (OR 0.80, 95% CI 0.69 to 0.94, NNT 43).

The following decision support rules contain links to this evidence summary:

References

1. Sudlow C, Lonn E, Pignone M, Ness A, Rihal C. Secondary prevention of ischaemic cardiac events. Clin Evid 2002 Jun;(7):124-60.  [PMID:12230641]

Copyright © 2022 Duodecim Medical Publications Limited.
ACE inhibitors for secondary prevention after myocardial infarction in patients with left ventricular dysfunction is a sample topic from the Evidence-Based Medicine Guidelines.

To view other topics, please or .

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. .